Article info
PDFClinical and epidemiological research
Extended report
Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab
- Correspondence to A Ruyssen-Witrand, Centre de Rhumatologie, Hôpital Purpan, 1 place du Dr Baylac, 31059 Toulouse Cedex 09, France; adruyssen{at}hotmail.com
Citation
Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab
Publication history
- Received June 24, 2011
- Accepted November 29, 2011
- First published February 25, 2012.
Online issue publication
October 25, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions